Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020108612 - USE OF C-MET ADC IN PREPARING DRUG FOR TREATING C-MET KINASE INHIBITOR RESISTANT DISEASE

Publication Number WO/2020/108612
Publication Date 04.06.2020
International Application No. PCT/CN2019/121943
International Filing Date 29.11.2019
IPC
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61K 31/537 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
537spiro-condensed or forming part of bridged ring systems
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
CPC
A61K 31/537
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
537spiro-condensed or forming part of bridged ring systems
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Applicants
  • 江苏恒瑞医药股份有限公司 JIANGSU HENGRUI MEDICINE CO., LTD. [CN]/[CN]
  • 苏州盛迪亚生物医药有限公司 SUZHOU SUNCADIA BIOPHARMACEUTICALS CO., LTD. [CN]/[CN]
  • 上海恒瑞医药有限公司 SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. [CN]/[CN]
Inventors
  • 蒋家骅 JIANG, Jiahua
  • 廖成 LIAO, Cheng
  • 张连山 ZHANG, Lianshan
  • 孙飘扬 SUN, Piaoyang
Agents
  • 北京戈程知识产权代理有限公司 GE CHENG & CO., LTD.
Priority Data
201811452566.230.11.2018CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) USE OF C-MET ADC IN PREPARING DRUG FOR TREATING C-MET KINASE INHIBITOR RESISTANT DISEASE
(FR) UTILISATION DE CONJUGUÉ ANTICORPS-MÉDICAMENT DE C-MET DANS LA PRÉPARATION D'UN MÉDICAMENT DESTINÉ À TRAITER UNE MALADIE RÉSISTANTE AUX INHIBITEURS DE LA KINASE C-MET
(ZH) 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途
Abstract
(EN)
The present disclosure provides a use of c-Met ADC in preparing a drug for treating a c-Met kinase inhibitor resistant disease. Specifically, the present disclosure provides a use of anti-c-Met antibody drug conjugate in preparing a drug for treating a c-Met kinase inhibitor resistant disease, particularly for non-small cell lung cancer treated by and resistant to c-Met kinase inhibitor. The anti-c-Met antibody drug conjugate is as shown in the description.
(FR)
La présente invention concerne l'utilisation d'un conjugué anticorps-médicament (CAM) de c-Met dans la préparation d'un médicament destiné à traiter une maladie résistante aux inhibiteurs de la kinase c-Met. L'invention concerne en particulier l'utilisation d'un conjugué anticorps-médicament anti-c-Met dans la préparation d'un médicament destiné au traitement d'une maladie résistante aux inhibiteurs de la kinase c-Met, en particulier du cancer du poumon non à petites cellules, traité par inhibiteur de kinase c-Met et résistant à celui-ci. Le conjugué anticorps-médicament anti-c-Met selon l'invention est tel que présenté dans la description.
(ZH)
本公开提供一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途。具体而言,本公开提供了一种抗c-Met抗体药物偶联物在在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途,特别是经c-Met激酶抑制剂治疗后耐药的非小细胞肺癌,所述的抗c-Met抗体药物偶联物如说明书所述。
Latest bibliographic data on file with the International Bureau